Pharma News

Eminence Business Media’s 2nd Annual Pharma Manufacturing & Automation Convention 2019” – A huge success

  • Posted on: 19 November 2019
  • By: PharmaTutor News

Eminence Business Media’s “2nd Annual Pharma Manufacturing & Automation Convention 2019” concluded on October 17th & 18th, 2019 at Hotel Radisson Blu Plaza Banjara Hills, Hyderabad. The theme of the summit was “From Ideation to Innovation: Aligning with trending market demands”. The event was an outstanding success with 150+ delegates attending the conference with Honeywell, Zenith Technologies, Caliber Group, UL &  Pharma Mantra partnering the event.

FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease

  • Posted on: 18 November 2019
  • By: Shalini.Sharma

U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.

EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2019 meeting

  • Posted on: 18 November 2019
  • By: Shalini.Sharma

The Committee recommended granting a marketing authorisation for Isturisa* (osilodrostat) for the treatment of Cushing’s syndrome, a rare disorder that occurs when the body produces too much corticosteroid hormone. It leads to patients experiencing weight gain, fat build-up on the face and bruising.

FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product

  • Posted on: 18 November 2019
  • By: Shalini.Sharma

Biological products play an increasingly central role in modern medicine, offering treatments for many serious illnesses. Commonly referred to as biologics, these medicines are generally made from natural or living sources, like animal and plant cells, and microorganisms such as bacteria or yeast, and developed using advanced science. They are usually more complex than other drugs and are particularly critical in the treatment of cancer and autoimmune conditions, such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.

IPA opposed amendment in Schedule K of D&C Rules by health ministry

Indian Pharmaceutical Association (IPA) strongly opposed the proposed amendment in Schedule K of Drugs & Cosmetics (D&C) Rules by health ministry. IPA is the largest association of Pharmacists in India & working not only for uplifting the pharmacy profession but also to ascertain that patients receives quality pharmaceutical care.

 

Synthetic DNA Technology applied as a Novel Strategy for Delivery of Anti-HIV Antibodies

  • Posted on: 12 November 2019
  • By: PharmaTutor News

Scientists at The Wistar Institute applied synthetic DNA-based technology to drive in vivo production of broadly neutralizing anti-HIV antibodies in small and large-animal models, providing proof of concept for a simple and effective next generation approach to HIV prevention and therapy. These results were published online in the Journal of Clinical Investigation.

IIHMR University Alumni Meet held at Delhi

  • Posted on: 11 November 2019
  • By: PharmaTutor News

IIHMR University organised its alumni meet at Indian Habitat Centre, New Delhi on 9 November 2019. As many as 100 alumni witnessed the meet. On the occasion, a poster on ‘Centre for Excellence & Block Chain Technology’ was also launched by the dignitaries including Ms. Shikha Mehra, Founder & CEO, Mainchain Research and Consulting, Dr. Pankaj Gupta, President, IIHMR U and Dr. S D Gupta, Chairman, IIHMR U.

Study Vaccine Protects Monkeys Against Four Types of Hemorrhagic Fever Viruses

  • Posted on: 9 November 2019
  • By: PharmaTutor News

Scientists funded by the National Institutes of Health have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa. The University of Texas Medical Branch in Galveston and Profectus BioSciences of New York are developing and testing the candidate quadrivalent VesiculoVax vaccine, with support from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and Redeemer’s University in Nigeria.

Pages